Choudhury Arup, Tariq Raseen, Jena Anuraag, Vesely Elissa Kinzelman, Singh Siddharth, Khanna Sahil, Sharma Vishal
Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Therap Adv Gastroenterol. 2022 Aug 19;15:17562848221118403. doi: 10.1177/17562848221118403. eCollection 2022.
Prolonged symptoms after COVID-19 are an important concern due to the large numbers affected by the pandemic.
To ascertain the frequency of gastrointestinal (GI) manifestations as part of long GI COVID.
A systematic review and meta-analysis of studies reporting GI manifestations in long COVID was performed.
Electronic databases (Medline, Scopus, Embase, Cochrane Central Register of Controlled Trials, and Web of Science) were searched till 21 December 2021 to identify studies reporting frequency of GI symptoms in long COVID. We included studies reporting overall GI manifestations or individual GI symptoms as part of long COVID. We excluded pediatric studies and those not providing relevant information. We calculated the pooled frequency of various symptoms in all patients with COVID-19 and also in those with long COVID using the inverse variance approach. All analysis was done using R version 4.1.1 using packages 'meta' and 'metafor'.
A total of 50 studies were included. The frequencies of GI symptoms were 0.12 [95% confidence interval (CI), 0.06-0.22, = 99%] and 0.22 (95% CI, 0.10-0.41, = 97%) in patients with COVID-19 and those with long COVID, respectively. The frequencies of abdominal pain, nausea/vomiting, loss of appetite, and loss of taste were 0.14 (95% CI, 0.04-0.38, = 96%), 0.06 (95% CI, 0.03-0.11, = 98%), 0.20 (95% CI, 0.08-0.43, = 98%), and 0.17 (95% CI, 0.10-0.27, = 95%), respectively, after COVID-19. The frequencies of diarrhea, dyspepsia, and irritable bowel syndrome were 0.10 (95% CI, 0.04-0.23, = 98%), 0.20 (95% CI, 0.06-0.50, = 97%), and 0.17 (95% CI, 0.06-0.37, = 96%), respectively.
GI symptoms in patients were seen in 12% after COVID-19 and 22% as part of long COVID. Loss of appetite, dyspepsia, irritable bowel syndrome, loss of taste, and abdominal pain were the five most common GI symptoms of long COVID. Significant heterogeneity and small number of studies for some of the analyses are limitations of the systematic review.
由于大量人群受到新冠疫情影响，新冠病毒感染后长期症状成为一个重要问题。
确定胃肠道（GI）表现作为新冠长期胃肠道症状一部分的发生率。
对报告新冠长期症状中胃肠道表现的研究进行系统综述和荟萃分析。
检索电子数据库（Medline、Scopus、Embase、Cochrane对照试验中心注册库和Web of Science）至2021年12月21日，以识别报告新冠长期症状中胃肠道症状发生率的研究。我们纳入报告作为新冠长期症状一部分的总体胃肠道表现或个别胃肠道症状的研究。我们排除儿科研究以及未提供相关信息的研究。我们使用逆方差法计算所有新冠患者以及新冠长期患者各种症状的合并发生率。所有分析使用R 4.1.1版本，借助“meta”和“metafor”软件包进行。
共纳入50项研究。新冠患者和新冠长期患者中胃肠道症状的发生率分别为0.12[95%置信区间（CI），0.06 - 0.22，I² = 99%]和0.22（95% CI，0.10 - 0.41，I² = 97%）。新冠病毒感染后腹痛、恶心/呕吐、食欲不振和味觉丧失的发生率分别为0.14（95% CI，0.04 - 0.38，I² = 96%）、0.06（95% CI，0.03 - 0.11，I² = 98%）、0.20（95% CI，0.08 - 0.43，I² = 98%）和0.17（95% CI，0.10 - 0.27，I² = 95%）。腹泻、消化不良和肠易激综合征的发生率分别为0.10（95% CI，0.04 - 0.23，I² = 98%）、0.20（95% CI，0.06 - 0.50，I² = 97%）和0.17（95% CI，0.06 - 0.37，I² = 96%）。
新冠患者中胃肠道症状发生率为12%，作为新冠长期症状一部分时为22%。食欲不振、消化不良、肠易激综合征、味觉丧失和腹痛是新冠长期症状中最常见的五种胃肠道症状。显著的异质性以及部分分析研究数量较少是该系统综述的局限性。
